SABCS 2022 Conference Coverage


 

SABCS 2022 Results of the Randomized, Multi-Dose Phase 2 SERENA-2 Trial: Camizestrant, a Next-Gen Oral SERD vs. Fulvestrant in Post-Menopausal Women With Advanced ER+/HER2- BC

237 views
December 15, 2022
Comments 0
Login to view comments. Click here to Login